Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: A comparison with p53 nuclear accumulation

Hong Lin Cheng, Barry Trink, Tzong Shin Tzai, Hsiao Sheng Liu, Shih Huang Chan, Chung Liang Ho, David Sidransky, Nan Haw Chow

Research output: Contribution to journalArticle

Abstract

Purpose: The c-met proto-oncogene encodes a receptor tyrosine kinase (Met) and has been shown to play a role in oncogenesis. Given that high titers of hepatocyte growth factor, the specific ligand for Met, are excreted in the urine and tend to reflect disease activity of bladder cancer, we performed this study to examine the clinical significance of Met in human bladder cancer. Materials and Methods: We studied the mRNA expression and genomic alteration of c-met in five bladder cancer cell lines. Significance of Met overexpression was then compared with p53 nuclear accumulation (TP53) in primary bladder cancer (n = 142 patients). Results: Expression of c-met mRNA tended to positively correlate with differentiation of cancer cell lines in the absence of point mutation. High expression of Met was found in seven cases (4.9%), low expression in 32 cases (22.5%), and negative expression in 103 cases (72.5%). Expression of Met was positively associated with histologic grade, stage classification, tumor size, and nodular tumor growth (P <.05, respectively); however, it was not related to TP53 status. Factors that predicted disease progression were tumor stage, Met status, and TP53 accumulation (P <.05, respectively). Indicators for poor long-term survival were invasive cancer, multiple tumors, and Met overexpression (P = .0006, .01, and .04, respectively). Conclusion: The c-met proto-oncogene plays a more important role in the progression of bladder carcinogenesis than p53. Evaluation of Met expression could identify a subset of bladder cancer patients who may require a more intensive treatment strategy.

Original languageEnglish (US)
Pages (from-to)1544-1550
Number of pages7
JournalJournal of Clinical Oncology
Volume20
Issue number6
DOIs
StatePublished - Mar 15 2002
Externally publishedYes

Fingerprint

Transitional Cell Carcinoma
Urinary Bladder
Urinary Bladder Neoplasms
Neoplasms
Proto-Oncogenes
Carcinogenesis
Cell Line
Messenger RNA
Hepatocyte Growth Factor
Receptor Protein-Tyrosine Kinases
Point Mutation
Disease Progression
Urine
Ligands
Survival
Growth

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder : A comparison with p53 nuclear accumulation. / Cheng, Hong Lin; Trink, Barry; Tzai, Tzong Shin; Liu, Hsiao Sheng; Chan, Shih Huang; Ho, Chung Liang; Sidransky, David; Chow, Nan Haw.

In: Journal of Clinical Oncology, Vol. 20, No. 6, 15.03.2002, p. 1544-1550.

Research output: Contribution to journalArticle

Cheng, Hong Lin ; Trink, Barry ; Tzai, Tzong Shin ; Liu, Hsiao Sheng ; Chan, Shih Huang ; Ho, Chung Liang ; Sidransky, David ; Chow, Nan Haw. / Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder : A comparison with p53 nuclear accumulation. In: Journal of Clinical Oncology. 2002 ; Vol. 20, No. 6. pp. 1544-1550.
@article{cb4d9fa6973b435dbf49e785f0171014,
title = "Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: A comparison with p53 nuclear accumulation",
abstract = "Purpose: The c-met proto-oncogene encodes a receptor tyrosine kinase (Met) and has been shown to play a role in oncogenesis. Given that high titers of hepatocyte growth factor, the specific ligand for Met, are excreted in the urine and tend to reflect disease activity of bladder cancer, we performed this study to examine the clinical significance of Met in human bladder cancer. Materials and Methods: We studied the mRNA expression and genomic alteration of c-met in five bladder cancer cell lines. Significance of Met overexpression was then compared with p53 nuclear accumulation (TP53) in primary bladder cancer (n = 142 patients). Results: Expression of c-met mRNA tended to positively correlate with differentiation of cancer cell lines in the absence of point mutation. High expression of Met was found in seven cases (4.9{\%}), low expression in 32 cases (22.5{\%}), and negative expression in 103 cases (72.5{\%}). Expression of Met was positively associated with histologic grade, stage classification, tumor size, and nodular tumor growth (P <.05, respectively); however, it was not related to TP53 status. Factors that predicted disease progression were tumor stage, Met status, and TP53 accumulation (P <.05, respectively). Indicators for poor long-term survival were invasive cancer, multiple tumors, and Met overexpression (P = .0006, .01, and .04, respectively). Conclusion: The c-met proto-oncogene plays a more important role in the progression of bladder carcinogenesis than p53. Evaluation of Met expression could identify a subset of bladder cancer patients who may require a more intensive treatment strategy.",
author = "Cheng, {Hong Lin} and Barry Trink and Tzai, {Tzong Shin} and Liu, {Hsiao Sheng} and Chan, {Shih Huang} and Ho, {Chung Liang} and David Sidransky and Chow, {Nan Haw}",
year = "2002",
month = "3",
day = "15",
doi = "10.1200/JCO.20.6.1544",
language = "English (US)",
volume = "20",
pages = "1544--1550",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "6",

}

TY - JOUR

T1 - Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder

T2 - A comparison with p53 nuclear accumulation

AU - Cheng, Hong Lin

AU - Trink, Barry

AU - Tzai, Tzong Shin

AU - Liu, Hsiao Sheng

AU - Chan, Shih Huang

AU - Ho, Chung Liang

AU - Sidransky, David

AU - Chow, Nan Haw

PY - 2002/3/15

Y1 - 2002/3/15

N2 - Purpose: The c-met proto-oncogene encodes a receptor tyrosine kinase (Met) and has been shown to play a role in oncogenesis. Given that high titers of hepatocyte growth factor, the specific ligand for Met, are excreted in the urine and tend to reflect disease activity of bladder cancer, we performed this study to examine the clinical significance of Met in human bladder cancer. Materials and Methods: We studied the mRNA expression and genomic alteration of c-met in five bladder cancer cell lines. Significance of Met overexpression was then compared with p53 nuclear accumulation (TP53) in primary bladder cancer (n = 142 patients). Results: Expression of c-met mRNA tended to positively correlate with differentiation of cancer cell lines in the absence of point mutation. High expression of Met was found in seven cases (4.9%), low expression in 32 cases (22.5%), and negative expression in 103 cases (72.5%). Expression of Met was positively associated with histologic grade, stage classification, tumor size, and nodular tumor growth (P <.05, respectively); however, it was not related to TP53 status. Factors that predicted disease progression were tumor stage, Met status, and TP53 accumulation (P <.05, respectively). Indicators for poor long-term survival were invasive cancer, multiple tumors, and Met overexpression (P = .0006, .01, and .04, respectively). Conclusion: The c-met proto-oncogene plays a more important role in the progression of bladder carcinogenesis than p53. Evaluation of Met expression could identify a subset of bladder cancer patients who may require a more intensive treatment strategy.

AB - Purpose: The c-met proto-oncogene encodes a receptor tyrosine kinase (Met) and has been shown to play a role in oncogenesis. Given that high titers of hepatocyte growth factor, the specific ligand for Met, are excreted in the urine and tend to reflect disease activity of bladder cancer, we performed this study to examine the clinical significance of Met in human bladder cancer. Materials and Methods: We studied the mRNA expression and genomic alteration of c-met in five bladder cancer cell lines. Significance of Met overexpression was then compared with p53 nuclear accumulation (TP53) in primary bladder cancer (n = 142 patients). Results: Expression of c-met mRNA tended to positively correlate with differentiation of cancer cell lines in the absence of point mutation. High expression of Met was found in seven cases (4.9%), low expression in 32 cases (22.5%), and negative expression in 103 cases (72.5%). Expression of Met was positively associated with histologic grade, stage classification, tumor size, and nodular tumor growth (P <.05, respectively); however, it was not related to TP53 status. Factors that predicted disease progression were tumor stage, Met status, and TP53 accumulation (P <.05, respectively). Indicators for poor long-term survival were invasive cancer, multiple tumors, and Met overexpression (P = .0006, .01, and .04, respectively). Conclusion: The c-met proto-oncogene plays a more important role in the progression of bladder carcinogenesis than p53. Evaluation of Met expression could identify a subset of bladder cancer patients who may require a more intensive treatment strategy.

UR - http://www.scopus.com/inward/record.url?scp=0037087754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037087754&partnerID=8YFLogxK

U2 - 10.1200/JCO.20.6.1544

DO - 10.1200/JCO.20.6.1544

M3 - Article

C2 - 11896103

AN - SCOPUS:0037087754

VL - 20

SP - 1544

EP - 1550

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 6

ER -